Workflow
Betta Pharmaceuticals Co., Ltd.(300558)
icon
Search documents
贝达药业(300558) - 2018 Q3 - 季度财报
2018-10-24 16:00
贝达药业股份有限公司 2018 年第三季度报告 2018 年 10 月 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计主 管人员)王铁奇声明:保证季度报告中财务报表的真实、准确、完整。 1 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 | 项目 | 年初至报告期期末金额 | 说明 | | --- | --- | --- | | 非流动资产处置损益(包括已计提资产减值准备的冲销部分) | -63,631.70 | | | 计入当期损益的政府补助(与企业业务密切相关,按照国家统一标准定额 | 22,908,489.54 | | | 或定量享受的政府补助除外) | | | | 除同公司正常经营业务相关的有效套期保值业务外,持有交易性金融资 产、交易性金融负债产生的公允价值变动损益,以及处置交易性金融资产、 | 2,563 ...
贝达药业(300558) - 2018 Q2 - 季度财报
2018-08-23 16:00
贝达药业股份有限公司 2018 年半年度报告 2018 年 08 月 2018 年半年度报告全文 | 目录 | | --- | | 第一节 重要提示、目录和释义 1 | | --- | | 第二节 公司简介和主要财务指标 5 | | 第三节 公司业务概要 8 | | 第四节 经营情况讨论与分析 12 | | 第五节 重要事项 25 | | 第六节 股份变动及股东情况 34 | | 第七节 优先股相关情况 37 | | 第八节 董事、监事、高级管理人员情况 38 | | 第九节 公司债相关情况 39 | | 第十节 财务报告 40 | | 第十一节 备查文件目录 122 | 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别 和连带的法律责任。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计主 管人员)王铁奇声明:保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构 ...
贝达药业(300558) - 2018 Q1 - 季度财报
2018-04-24 16:00
2018 ᒤㅜаᆓᓖᣕ 䍍䗮㦟ъ㛑ԭᴹ䲀ޜਨ 2018 ᒤ 4 ᴸ | ⴞᖅ | | --- | | ㅜа㢲 | | 䟽㾱ᨀ⽪ 1 | | | --- | --- | --- | --- | | ㅜҼ㢲 | ޜ ਨสᵜ ߥᛵ | | 2 | | ㅜй㢲 | 䟽㾱һ亩 | 7 | | | ㅜഋ㢲 | 䍒࣑ᣕ㺘 | 13 | | | ㅜӄ㢲 | ༷ḕ᮷Ԧⴞᖅ | 27 | | 2018ᒤㅜаᆓᓖᣕޘ᮷ ㅜа㢲 䟽㾱ᨀ⽪ ޜਨ㪓һՊǃⴁһՊ৺㪓һǃⴁһǃ儈㓗㇑⨶Ӫઈ؍䇱ᆓᓖᣕᇩⲴⵏ ᇎǃ߶⺞ǃᆼᮤˈнᆈ൘㲊ۇٴ䇠䖭ǃ䈟ሬᙗ䱸䘠ᡆ䟽བྷ䚇┿ˈᒦᣵњ઼࡛䘎 ᑖⲴ⌅ᖻ䍓ԫDŽ ᡰᴹ㪓һ൷ᐢࠪᑝҶᇑ䇞ᵜ⅑ᆓᓖᣕⲴ㪓һՊՊ䇞DŽ ޜਨ䍏䍓Ӫбࡇ᰾ǃѫ㇑Պ䇑ᐕ䍏䍓Ӫ㤳ᔪࣻ৺Պ䇑ᵪᶴ䍏䍓Ӫ(Պ䇑ѫ ㇑Ӫઈ)⦻䫱ཷ༠᰾˖؍䇱ᆓᓖᣕѝ䍒࣑ᣕ㺘Ⲵⵏᇎǃ߶⺞ǃᆼᮤDŽ 1 2018ᒤㅜаᆓᓖᣕޘ᮷ ߥᛵਨสᵜޜ ㅜҼ㢲 аǃѫ㾱Պ䇑ᮠᦞ઼䍒࣑ᤷḷ | | ᵜᣕ੺ᵏ | кᒤ਼ᵏ | ᵜᣕ੺ᵏ∄кᒤ਼ᵏ໎߿ | | --- | --- | --- | --- | | 㩕ъᙫ᭦ ˅ݳ˄ޕ | 284,615,012.67 | 229,539 ...
贝达药业(300558) - 2017 Q4 - 年度财报
2018-04-09 16:00
2017 年年度报告 贝达药业股份有限公司 2018 年 4 月 | 第一节 重要提示和释义 1 | | --- | | 第二节 公司简介和主要财务指标 5 | | 第三节 公司业务概要 9 | | 第四节 经营情况讨论与分析 13 | | 第五节 重要事项 33 | | 第六节 股份变动及股东情况 56 | | 第七节 优先股相关情况 62 | | 第八节 董事、监事、高级管理人员和员工情况 63 | | 第九节 公司治理 74 | | 第十节 公司债券相关情况 80 | | 第十一节 财务报告 81 | | 第十二节 备查文件目录 173 | | 第十三节 摘要数据报送 174 | 2017 年年度报告 第一节 重要提示和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和连 带的法律责任。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计主 管人员)王铁奇声明:保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司 ...
贝达药业(300558) - 2017 Q3 - 季度财报
2017-10-26 16:00
Revenue Performance - The company's revenue for the period reached approximately $2.57 billion, representing an 18.69% increase compared to the previous year[5] - The company reported a revenue of 266,500 million, reflecting a growth of 26.7% year-over-year[9] - The company reported total revenue of $323.69 million for Q3 2017, representing a 110.26% increase compared to the previous quarter[14] - Future guidance indicates an expected revenue growth of 118.27% for the next quarter, projecting $369.94 million[15] - The company reported total revenue of $401 million for the year ending December 31, 2016, representing a 10% increase compared to the previous year[18] - The company reported total revenue of $941,771,012.65, a significant increase from $1,382,814,821.94 in the previous period, indicating a growth trend[27] - Total revenue for the period reached $2,605,863,227.61, an increase from $2,181,570,720.57 in the previous period, representing a growth of approximately 19.4%[29] - The company's revenue for the period was $768.28 million, compared to $787.36 million in the previous period, reflecting a decrease of approximately 2%[41] - The company's revenue for the latest quarter was approximately $859.91 million, compared to $908.40 million in the previous quarter, reflecting a decrease of about 5.7%[44] - The company's revenue for the latest quarter was approximately $1,031.65 million, an increase from $906.79 million in the previous quarter, representing a growth of about 13.8%[48] User Engagement - User engagement metrics showed a decline, with a 37.04% drop in average daily active users to 0.17 million[5] - User data showed a total of 80,064,000 active users, representing a 19.97% increase[8] - User data showed a significant increase in active users, with a growth rate of 1350.01% in a specific segment, reaching $25.50 million[14] - User data showed an increase in active users by 20% year-over-year, indicating strong customer engagement[18] - User data showed a significant increase, with 1,664,092,214.96 in active users compared to 798,755,898.63 previously, indicating a growth of about 108.3%[29] - User data showed an increase in active users, with a total of 105.23 million active users, up from 94.58 million, indicating a growth of 11.67%[34] - User data showed a significant increase, with 306.34 million users reported, up from 293.22 million, marking an increase of about 4%[41] - User data showed a significant increase, with a total of 44,058,239 users, up from 73,862,536 users in the previous period, indicating a decline of approximately 40%[44] - User data showed a significant increase, with total users reaching 1,649,887, up from 1,649,887 in the previous period[48] Net Income and Profitability - The company reported a net income of $41.63 million, reflecting a significant decrease of 30.88% year-over-year[6] - The company reported a net loss of $119.16 million, a 75.34% decrease compared to the previous year[15] - The net income for the same period was $72.18 million, which is a 1.8% increase year-over-year[18] - The company reported a net income of $476,017,905.33, which is a substantial increase from $205,424,350.50 in the previous period, showcasing improved profitability[25] - The company reported a net income of $107,635,444.59, up from $70,293,413.21, reflecting a year-over-year increase of approximately 53.2%[28] - The net income for the period was $10.18 million, compared to $8.10 million in the previous year, reflecting a growth of 25.92%[34] - The net income for the company was reported at -$1.35 million, a decline from a net income of $1.70 million in the previous period[41] - The company reported a net income of $88.74 million, which is a 36.6% increase from $64.96 million in the prior quarter[44] - The company reported a net income of $186.39 million, compared to $151.13 million in the previous quarter, indicating a growth of approximately 23.3%[48] Research and Development - Research and development expenses increased by 40.13%, indicating a strong commitment to innovation and new technology[5] - Research and development investments are expected to rise, with a projected budget of $200 million for new technologies[15] - The company has allocated $1500 million for research and development in new technologies and products[17] - The company reported a significant increase in R&D spending, which is expected to yield a 2.85% improvement in product offerings, amounting to 11,412,000[8] - Research and development expenses increased to $47,292,816.65, up from $21,519,305.79, indicating a focus on innovation[28] - The company has allocated $100 million for research and development in new technologies over the next year[46] - The company reported a 50% increase in R&D spending compared to the previous year, reflecting its commitment to innovation[17] Future Guidance and Strategic Plans - Future guidance indicates a projected revenue growth of 6.54% for the next quarter, with expectations to reach around $2.05 billion[5] - The company provided a future outlook with a performance guidance of 14.33% growth, targeting 57,456,000 users[8] - Future guidance indicates a projected revenue growth of 5% to 7% for the upcoming fiscal year[18] - Future guidance indicates expected revenue growth of 15% to 20% for the next quarter, driven by new product launches and market expansion strategies[29] - Future guidance indicates expected revenue growth of 10% for the next quarter, projecting revenues to reach approximately $1.1 billion[45] - The company plans to implement new strategies to improve user retention and engagement metrics in the coming quarters[6] - Overall, the company is optimistic about future growth despite current challenges, with a focus on strategic investments and market expansion[6] - The company plans to implement new marketing strategies to improve brand visibility and customer acquisition in the upcoming quarters[41] Market Expansion and Acquisitions - The company is exploring potential acquisitions to enhance its market position and diversify its product offerings[6] - The company is focusing on market expansion, with a projected increase of 5.84% in user engagement, equating to 23,425,560 users[8] - The company is focusing on expanding its market presence, particularly in the New Jersey area, with plans to open new facilities[17] - The overall market strategy includes potential mergers and acquisitions to enhance growth and market presence[15] - A strategic acquisition is anticipated to enhance the company's market position, with an expected revenue boost of 21,600,000, reflecting a 5.39% increase[8] - The company is planning market expansion into three new regions, which is anticipated to increase user base by 20%[45] - A strategic acquisition is planned to enhance technological capabilities, with an estimated investment of $50 million[41] - A strategic acquisition was completed for $10,000,000.00, expected to enhance operational efficiencies and product offerings[28] - A strategic acquisition was completed, valued at $200,000,000.00, aimed at bolstering the company's capabilities in pharmaceuticals[24]
贝达药业(300558) - 2017 Q2 - 季度财报
2017-08-21 16:00
贝达药业股份有限公司 2017 年半年度报告 (公告编号:2017-068) 2017 年 08 月 | 目录 | | --- | | 第一节 | 重要提示、目录和释义 | 1 | | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | 5 | | 第三节 | 公司业务概要 | 8 | | 第四节 | 经营情况讨论与分析 | 13 | | 第五节 | 重要事项 | 26 | | 第六节 | 股份变动及股东情况 | 37 | | 第七节 | 优先股相关情况 | 42 | | 第八节 | 董事、监事、高级管理人员情况 | 43 | | 第九节 | 公司债相关情况 | 44 | | 第十节 | 财务报告 | 45 | | 第十一节 | 备查文件目录 | 121 | 2017 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别 和连带的法律责任。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计 主管人员)王铁奇声明:保证本半年度报告中财务报告 ...
贝达药业(300558) - 2017 Q1 - 季度财报
2017-04-26 16:00
2017 年第一季度报告 贝达药业股份有限公司 2017 年 4 月 2017 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人丁列明、主管会计工作负责人范建勋及会计机构负责人(会计主 管人员)王铁奇声明:保证季度报告中财务报表的真实、准确、完整。 1 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入(元) | 229,539,932.98 | 274,926,779.02 | -16.51% | | 归属于上市公司股东的净利润(元) | 75,549,674.60 | 103,238,738.46 | -26.82% | | 归属于上市公司股东的扣除非经常性损 益的净利润(元) | 49,252,805.86 | 75,499,192.22 | -34 ...
贝达药业(300558) - 2016 Q4 - 年度财报
2017-04-05 16:00
本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的 真实、准确、完整,不存在虚假记载、误导性陈述或重大遗漏,并承担个别和 连带的法律责任。 公司负责人丁列明、主管会计工作负责人徐素兰及会计机构负责人(会计主 管人员)王铁奇声明:保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 | 目录 | | --- | | 第一节 重要提示和释义 1 | | --- | | 第二节 公司简介和主要财务指标 5 | | 第三节 公司业务概要 8 | | 第四节 经营情况讨论与分析 13 | | 第五节 重要事项 29 | | 第六节 股份变动及股东情况 53 | | 第七节 优先股相关情况 59 | | 第八节 董事、监事、高级管理人员和员工情况 60 | | 第九节 公司治理 70 | | 第十节 公司债券相关情况 76 | | 第十一节 财务报告 77 | | 第十二节 备查文件目录 151 | 2016 年年度报告 第一节 重要提示和释义 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者 的实质承诺,投资者及相关人士均应当对此保持足够的风险认识,并且应 ...